* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。
* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。
* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数.HSI大幅上扬27.6%。
* 恒生香港上市生物科技指数.HSHKBIO早盘收高1.1%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 田镧沁)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.